Chugai Pharmaceutical Co., Ltd. (TSE: 4519)
Health Care · Pharmaceuticals · JP
¥6,019.00
-1.44% today · -18.1% 1Y
Chugai Pharmaceutical Co., Ltd. (TSE: 4519) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $62.54B and employs 5,104 people.
Over the last twelve months the share price has lost 18.1%, trading between 5.97K and 10.70K.
Tweenvest scores Chugai Pharmaceutical Co., Ltd. across four factors: quality 89/100, value 65/100, growth 56/100, dividend 40/100. Its strongest factor is quality.
4519 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $62.54B
- Revenue (TTM)
- $8.26B
- P/E
- 21.01
- EPS
- 286.42
- Dividend yield
- 2.16%
- Beta (5Y)
- 0.56
- 52-week high
- ¥10,700.00
- 52-week low
- ¥5,974.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.65B
- Employees
- 5,104
- Next earnings
- —
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
- ISIN
- JP3519400000
- Founded
- 1925
- Listed since
- Mar 2, 1956
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Bristol-Myers Squibb CompanyNYSE: BMY | $120.77B | $57.25 | -3.16% |
| SanofiENXTPA: SAN | $95.94B | €71.62 | +0.14% |
| GSK plcLSE: GSK | $92.79B | £17.61 | +0.63% |
| Merck KGaAXTRA: MRK | $67.11B | €138.40 | +0.40% |
| Takeda Pharmaceutical Company LimitedTSE: 4502 | $58.92B | ¥5,843.00 | +0.46% |
| Bayer AktiengesellschaftXTRA: BAYN | $48.15B | €43.73 | -0.09% |
| Teva Pharmaceutical Industries LimitedNYSE: TEVA | $47.89B | $41.37 | +0.66% |
| Galderma Group AGSWX: GALD | $46.30B | CHF168.65 | +2.24% |
Figures last refreshed Oct 11, 2026.